| Venetoclax and obinutuzumab in patients with CLL and coexisting conditions K Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ... New England Journal of Medicine 380 (23), 2225-2236, 2019 | 858 | 2019 |
| Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open … O Al-Sawaf, C Zhang, M Tandon, A Sinha, AM Fink, S Robrecht, ... The Lancet Oncology 21 (9), 1188-1200, 2020 | 298 | 2020 |
| Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations R Weinkove, P George, N Dasyam, AD McLellan Clinical & translational immunology 8 (5), e1049, 2019 | 262 | 2019 |
| Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia JR Brown, B Eichhorst, P Hillmen, W Jurczak, M Kaźmierczak, ... New England Journal of Medicine 388 (4), 319-332, 2023 | 193 | 2023 |
| Managing haematology and oncology patients during the COVID‐19 pandemic: interim consensus guidance R Weinkove, ZK McQuilten, J Adler, MR Agar, E Blyth, AC Cheng, ... Medical Journal of Australia 212 (10), 481-489, 2020 | 166 | 2020 |
| Fibrinogen concentrate for acquired hypofibrinogenaemic states R Weinkove, S Rangarajan Transfusion Medicine 18 (3), 151-157, 2008 | 147 | 2008 |
| Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014 S Fleming, CK Yannakou, GM Haeusler, J Clark, A Grigg, CH Heath, ... Internal medicine journal 44 (12b), 1283-1297, 2014 | 136 | 2014 |
| Venetoclax and obinutuzumab in chronic lymphocytic leukemia K Fischer, O Al-Sawaf, AM Fink, M Dixon, J Bahlo, S Warburton, TJ Kipps, ... Blood, The Journal of the American Society of Hematology 129 (19), 2702-2705, 2017 | 132 | 2017 |
| Non-invasive detection of anaemia using digital photographs of the conjunctiva S Collings, O Thompson, E Hirst, L Goossens, A George, R Weinkove PloS one 11 (4), e0153286, 2016 | 99 | 2016 |
| A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia J Weng, P Lai, L Qin, Y Lai, Z Jiang, C Luo, X Huang, S Wu, D Shao, ... Journal of Hematology & Oncology 11, 1-12, 2018 | 97 | 2018 |
| NKT cell-dependent glycolipid–peptide vaccines with potent anti-tumour activity RJ Anderson, BJ Compton, C Tang, A Authier-Hall, CM Hayman, ... Chemical science 6 (9), 5120-5127, 2015 | 75 | 2015 |
| Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial SJ Stanworth, S Killick, ZK McQuilten, M Karakantza, R Weinkove, ... British journal of haematology 189 (2), 279-290, 2020 | 65 | 2020 |
| Techniques for predicting a favourable response to renal angioplasty in patients with renovascular disease J Radermacher, R Weinkove, H Haller Current Opinion in Nephrology and Hypertension 10 (6), 799-805, 2001 | 60 | 2001 |
| A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients O Gasser, KJ Sharples, C Barrow, GM Williams, E Bauer, CE Wood, ... Cancer Immunology, Immunotherapy 67, 285-298, 2018 | 57 | 2018 |
| Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma MK Hunn, KJ Farrand, KWR Broadley, R Weinkove, P Ferguson, RJ Miller, ... Clinical Cancer Research 18 (23), 6446-6459, 2012 | 57 | 2012 |
| Low-dose thalidomide in myelofibrosis R Weinkove, JT Reilly, MF McMullin, NJ Curtin, D Radia, CN Harrison Haematologica 93 (7), 1100-1101, 2008 | 49 | 2008 |
| Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic P Di Ciaccio, G McCaughan, J Trotman, PJ Ho, CY Cheah, ... Internal Medicine Journal 50 (6), 667-679, 2020 | 46 | 2020 |
| T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells Y Nouri, R Weinkove, R Perret Journal for ImmunoTherapy of Cancer 9 (11), 2021 | 41 | 2021 |
| Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial P Hillmen, B Eichhorst, JR Brown, N Lamanna, SM O'Brien, CS Tam, ... Journal of Clinical Oncology 41 (5), 1035, 2023 | 38 | 2023 |
| Chimeric antigen receptor T‐cell therapies: Optimising the dose N Dasyam, P George, R Weinkove British Journal of Clinical Pharmacology 86 (9), 1678-1689, 2020 | 37 | 2020 |
Gavin F. PainterFerrier Research Institute, Victoria University of WellingtonBestätigte E-Mail-Adresse bei vuw.ac.nz
